CJC-1295 (with DAC) research peptide is supplied to qualified Canadian institutions as a characterized laboratory material for in vitro GHRH-receptor and albumin-conjugation studies. The compound is a GHRH(1-29) analogue extended with a lysine-linked maleimidopropionic acid drug-affinity complex (DAC).

In vitro, the DAC moiety is designed to form a covalent adduct with serum albumin, which is why the analogue is used when an experimental design must distinguish short-window Modified GRF (1-29) occupancy from an albumin-bound species. Typical assays record GHRH-receptor activation, second-messenger readouts, or albumin-binding / conjugate-stability measurements relative to the non-DAC analogue. This listing describes receptor and bioconjugate chemistry in experimental systems only.

The material is offered as a lyophilized vial. Identity data (CAS 446262-90-4, formula C165H269N47O46, molecular weight 3647.2 g/mol, PubChem CID 91971820) are listed on the specification table. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner and released against the stated HPLC purity for that lot (≥98% by HPLC, lot-specific). Identity, chromatographic purity, and related analytical results are documented on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.